Amplyx Overview
- Founded
- 2006

- Status
- Private
- Employees
- 29

- Latest Deal Type
- Series C
- Latest Deal Amount
- $91.3M

- Investors
- 24
Amplyx General Information
Description
Developer of antifungal agents intended to treat invasive fungal infections. The company's antifungal agents use both intravenous and oral formulations to address the need for treatment in both the hospital setting and continued convenient treatment after discharge from hospital, enabling patients undergoing chemotherapy and other immunosuppressive treatments, with compromised immune systems to get proper treatment for life-threatening invasive fungal infections due to candida, aspergillus and rare molds.
Contact Information
- 12730 High Bluff Drive
- Suite 160
- San Diego, CA 92130
- United States
Amplyx Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
5. Later Stage VC (Series C) | 09-Jan-2020 | $91.3M | 00000 | 00000 | Completed | Generating Revenue |
4. Later Stage VC (Series B) | 28-Feb-2017 | 000.00 | 000.00 | 0000 | Completed | Generating Revenue |
3. Accelerator/Incubator | 28-Feb-2017 | 00.00 | Completed | Generating Revenue | ||
2. Grant | 01-Jan-2017 | $11.3M | $2.3M | Completed | Generating Revenue | |
1. Early Stage VC (Series A) | 01-Jan-2011 | $2.3M | $2.3M | 000 | Completed | Generating Revenue |
Amplyx Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series C | 000,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Series B | 000,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Series A | 8,243,027 | $0.001000 | 8% | $0.27 | $0.27 | 1x | $0.27 | 2.04% |
Amplyx Comparisons
Industry
0000000
000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialAmplyx Competitors (28)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Samumed | Private Equity-Backed | San Diego, CA | 000 | 00000 | 000000000 - | 00000 |
000 | Venture Capital-Backed | Manchester, United Kingdom | 00 | 00000 | 00000000000 | 00000 |
000000 00000000000 | Private Equity-Backed | Copenhagen, Denmark | 0000 | 000000000000 | ||
00000 000000000000 | Corporation | NY | 0 | 00.000 | 00000000 | 00.000 |
0000000 | Venture Capital-Backed | Wuppertal, Germany | 00 | 000.00 | 0000000000 | 000.00 |
Amplyx Executive Team (15)
Amplyx Board Members (12)
Name | Representing | Role | Since |
---|---|---|---|
Anand Mehra MD | Sofinnova Investments | Board Member | 000 0000 |
Edward Mathers | Self | Board Member | 000 0000 |
Johan Kördel Ph.D | Lundbeckfonden | Board Member | 000 0000 |
Maha Katabi Ph.D | Self | Board Member | 000 0000 |
Mark Chin | Arix Bioscience | Board Observer | 000 0000 |
Amplyx Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialAmplyx Investors (24)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Adage Capital Management | Hedge Fund | Minority | 000 0000 | 000000 0 | |
Arix Bioscience | Venture Capital | Minority | 000 0000 | 000000 0 | |
Generation Ventures (Palo Alto) | Venture Capital | Minority | 000 0000 | 000000 0 | |
Lundbeckfonden | Limited Partner | Minority | 000 0000 | 000000 0 | |
Lundbeckfond Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |